Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3207485 | 0.99 | OPRM1 (0.50) | OPRM1OPRL1OPRD1OPRK1SLC6A3 | |
| SCHEMBL28914563 | 0.79 | OPRM1 (0.69) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| Bromide SCHEMBL10842432 | 0.76 | MAOA (0.44) | OPRM1OPRL1OPRD1OPRK1SLC6A3 | |
| SCHEMBL4204848 | 0.76 | OPRM1 (0.60) | OPRM1OPRL1OPRD1OPRK1SLC6A3 | |
| SCHEMBL17493640 | 0.74 | OPRM1 (0.58) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL4989701 | 0.74 | OPRM1 (0.58) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL3218429 | 0.74 | POLB (0.40) | OPRM1OPRD1SLC6A3SIGMAR1NPC1 | |
| SCHEMBL8425548 | 0.73 | OPRL1 (0.47) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27656058 | 0.73 | OPRM1 (0.59) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL3216979 | 0.73 | MEN1 (0.41) | OPRM1OPRD1SLC6A3SIGMAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678834-B2 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2010-03-16 | — | — | US | claimed |
| EP-1406859-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-01-02 | — | — | EP | claimed |
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| EP-1406859-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008371-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | claimed |
| US-7678834-B2 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1406859-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1406859-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003008371-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | ADRA2C, OPRD1, OPRK1 | OPRM1 6/4885OPRL1 4/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.